Breaking News

SGS Adds Viral Challenge Testing Facility

February 15, 2013

To include a 12-bed quarantine unit

SGS is expanding its Clinical Pharmacology Unit in Antwerp, Belgium with a Viral Challenge Testing facility that will include a 12-bed, biosafety level 2-Q compliant, quarantine facility, allowing the company to conduct highly specialized clinical trials.
The quarantine facility incorporates a negative pressure system, which includes individual compartments for infected volunteers, and a dedicated lab equipped with a flow cabinet, acid cabinet, workspace and workflows to handle specific (viral) cultures using HEPA-filtering and an airlock system. The facility also enables detailed assessment of immune parameters that help identify immunological correlations of infection and illness.
“This unique, European viral challenge testing facility enhances SGS’s service offering for our clients in the fields of infectious disease and vaccine development, allowing clients a chance to improve screening and development of their compounds” said Dr. Steven Ramael, SGS Life Science Services medical director. “Although the model does not necessarily reflect all parameters relevant to community-acquired infection, it does provide for a carefully controlled, systematic, and efficient method in which a number of variables can be controlled or even eliminated, with the subjects continuously monitored in a sequestered environment that minimizes safety risks.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016